MORE►
cancer drugs
Researchers found that deleting or degrading a protein called ZFP574 eliminates leukemic B cells (blue) over nonmalignant B cells in vivo. [Photo: UTSW]
UT Southwestern Researchers Target a Protein To Fight Leukemia, Lymphoma
by David Seeley | Aug 6, 2024
A study co-led by UTSW's Jin Huk Choi, Ph.D., and Nobel Prize winner Bruce Beutler, M.D., found that targeting a gene-produced protein called ZFP574 "reduced the amount of malignant B cells by as much as 92%." Their findings could lead to new treatments for leukemias and lymphomas—and potentially other cancers, too.
by Dallas Innovates | Staff Report |
Mar 1, 2023
Dallas-based Celanese Corporation has announced a collaboration with Alessa Therapeutics for developing a new oncology drug product, by utilizing the Celanese VitalDose EVA drug delivery platform. "Our new collaboration with Alessa Therapeutics underscores our commitment to optimize therapeutics through drug delivery innovation for oncology patients,” said Karen Chen, global business strategy leader for oncology at
Celanese.
MORE►
by David Seeley |
Jan 30, 2023
Dallas' Mark Cuban Cost Plus Drug Company announced a collaboration today with Houston-based OncoPower that will enable cancer patients using OncoPower to look up pricing and order less expensive medications.
OncoPower offers a free app and website with a social media-style format where patients can access professionals including dietitians and behavioral therapists, as well as cancer education and meditation content, tools for treatment adherence, and clinical trial mapping.
MORE►
by David Seeley |
Jun 22, 2022
The startup—which discovers and develops immuno-oncology therapeutics for cancer patients—was an inaugural tenant of BioLabs Pegasus Park, a 37,000-square-foot coworking laboratory and office space that opened in March. Aakha had previously been working out of interim space managed by BioLabs at UT Southwestern.
“With the premier facility and synergies available within Pegasus Park, we moved from concept to a solid preclinical stage company in the course of one year," Aakha Founder and CEO Hemanta Baruah said.
MORE►
